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Available online 5 December 2018Purpose: Differentiating between Dravet syndrome and non-Dravet SCN1A-related phenotypes is important
for prognosis regarding epilepsy severity, cognitive development, and comorbidities. When a child is
diagnosed with genetic epilepsy with febrile seizures plus (GEFS+) or febrile seizures (FS), accurate prognostic
information is essential as well, but detailed information on seizure course, seizure freedom, medication use,
and comorbidities is lacking for this milder patient group. In this cross-sectional study, we explore disease
characteristics in milder SCN1A-related phenotypes and the nature, occurrence, and relationships of
SCN1A-related comorbidities in both patients with Dravet and non-Dravet syndromes.
Methods: A cohort of 164 Dutch participants with SCN1A-related seizures was evaluated, consisting of 116
patients with Dravet syndrome and 48 patients with either GEFS+, febrile seizures plus (FS+), or FS.
Clinical data were collected from medical records, semi-structured telephone interviews, and three
questionnaires: the FunctionalMobility Scale (FMS), the Pediatric Quality of Life Inventory (PedsQL)Measurement
Model, and the Child or Adult Behavior Checklists (CBCL/ABCL).
Results:Walking disabilities and severe behavioral problems affect 71% and 43% of patients with Dravet syndrome
respectively and are almost never present in patients with non-Dravet syndromes. These comorbidities are strongly
correlated to lower quality-of-life (QoL) scores. Less severe comorbidities occur in patients with non-Dravet
syndromes: learning problems and psychological/behavioral problems are reported for 27% and 38% respectively.
The average QoL score of the non-Dravet group was comparable with that of the general population. The majority
of patients with non-Dravet syndromes becomes seizure-free after 10 years of age (85%).
Conclusions: Severe behavioral problems and walking disabilities are common in patients with Dravet syndrome
and should receive speciﬁc attention during clinical management. Although the epilepsy course of patients
with non-Dravet syndromes is much more favorable, milder comorbidities frequently occur in this group as well.
Our results may be of great value for clinical care and informing newly diagnosed patients and their parents
about prognosis.t, the Netherlands
Lange).







Pathogenic variants in SCN1A can cause several different epilepsy
syndromes, with varying disease severities [1–5]. The most common
and severe associated condition is Dravet syndrome,which is character-
ized by intractable epileptic seizures and a slowing of the psychomotor
development in the second year of life, which results in mild to severe
intellectual disability (ID).Walking difﬁculties and behavioral problems
are common comorbidities [6–9]. Milder phenotypes include genetic
epilepsy with febrile seizures plus (GEFS+) syndrome and febrile.
ccess article underseizures (FS and febrile seizures plus (FS+)), in which usually no ID is
present, and the epilepsy has a milder course [4,10]. Although the
majority of school-aged, adolescent, and adult patients with SCN1A-
related disease can easily be classiﬁed as having Dravet syndrome or
not, these different phenotypes may have a similar presentation at
onset [11,12].
SCN1A encodes for the α-subunit of a neuronal sodium channel,
Nav1.1. Pathogenic variants cause a reduction in sodium currents in
gamma-aminobutyric acid (GABA)-ergic inhibitory interneurons,
which leads to hyperexcitability of neuronal networks and the occur-
rence of seizures [13,14]. These reduced sodium currents, furthermore,
impair Purkinje cells, causing motor disorders [15,10] and contribute
to the development of behavioral problems and cognitive disabilitiesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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dromes can be partly explained by the consequences of different muta-
tion types: pathogenic variants that lead to a complete loss of function
of the channel are virtually always associated with severe phenotypes
whereas milder disturbances in channel function usually cause milder
phenotypes [17]. However, in clinical practice, it remains difﬁcult to
fully predict the effects of all variants on channel function.
Differentiating between Dravet syndrome and non-Dravet SCN1A-
related phenotypes is understandably of extreme importance for fami-
lies and physicians. The presence or absence of ID and the frequency
and severity of seizures both signiﬁcantly alter the level of care an
affected child requires. Furthermore, severe comorbidities, such as
walking disabilities or behavioral problems, are frequently reported in
Dravet syndrome [7–9,18–23] andmay pose a heavy burden on affected
families. Behavioral problems have been identiﬁed as the strongest
independent predictor for lower quality-of-life (QoL) scores [24]
and are reported to often be a cause of stress and concern for parents
[23,25]. Motor disorders have been shown to contribute signiﬁcantly
to lower health-related QoL (HRQoL) scores as well [24].
However, also, when a child is diagnosed with a milder SCN1A-
related disorder, such as GEFS+ or FS, accurate information about the
disease course and prognosis is essential. Many studies have reported
on the clinical spectrum of different SCN1A-related syndromes [12,17,
26], but detailed information on seizure course, seizure freedom,
medication use, and comorbidities is lacking for the milder patient
group. Although ID is thought to be exclusive to patients with Dravet
syndromes, there are reports of patients with non-Dravet syndromes
that show a mild cognitive impairment or neuropsychiatric symptoms
[27–29]. However, the incidence of these problems in patients with
non-Dravet SCN1A-related epilepsy is unknown, as they are mostly
described in case reports.
We describe here the detailed clinical data of a large cohort of
Dutch patients affected by SCN1A pathogenic variants (n = 164),
consisting of patients with Dravet syndrome as well as GEFS+, FS+,
or FS. We explore the nature, occurrence, and relationships of
SCN1A-related comorbidities in both the Dravet and non-Dravet
groups, to improve the counseling of patients and their parents. We
furthermore give a detailed overview of the disease course of
patients with non-Dravet syndromes to provide more insight in the
clinical spectrum of the less severe SCN1A-related disorders.
2. Methods
2.1. Participants
A previously described cohort [11,30] of 164 patients affected by
SCN1A-related seizures was included in this study. Only symptomatic
participantswith heterozygous pathogenic or likely pathogenic variants
(classes IV and V, according to the American College ofMedical Genetics
and Genomics criteria [31]) in SCN1Awere included. All eligible individ-
uals of at least 4 years of age known to the University Medical Center
Utrecht were approached. Patients below the age of 4 years were ex-
cluded since syndrome classiﬁcation and estimation of disease severity
are less reliable for younger children. Informed consent was obtained
from participants or their legal caretakers, according to the Declaration
of Helsinki. The study was approved by the Ethical Committee of the
University Medical Center Utrecht.
2.2. Clinical data
Detailed clinical data were retrospectively collected from medical
records of all participants, and a semi-structured telephone interview
was conducted when possible at the time of inclusion (n = 155).
Interviews were conducted with participants themselves if they were
adults andmentally competent; in all other cases, interviews were con-
ducted with parents of patients. Participants, or parents of participants,were asked the kind of education the participants were following or had
followed andwhether they had any learning problems or psychological
problems. If parents of patients were interviewed and not the patients
themselves, they were also asked whether their children showed any
behavioral problems (for other patients reported as missing data). The
same information was extracted from medical ﬁles. Furthermore,
three questionnaires were completed by participants in speciﬁc age
groups, or their parents, at the time of inclusion:
• The Dutch version of the Functional Mobility Scale (FMS), to classify
the general functional mobility in six categories for children aged
4–18 years [32] (Hugh Williamson Gait Laboratory, The Royal
Children's Hospital Melbourne, Australia, Part of the Gait CCRE,
www.rch.org.au/gait, Graham 2004);
• The Dutch version of the PedsQL Measurement Model, to measure
HRQoL on a 0–100 scale for participants aged 0–25 years [33];
• The Dutch parent report version of the Child Behavior Checklist
1.5–5 years (CBCL 1.5–5) or 6–18 years (CBCL), or the Dutch version
of the Adult Behavior Checklist 18–59years (ABCL) to evaluate behav-
ioral and emotional problems [34,35]. Behavioral problems in the
clinical range on the “total problems” scale are reported (p-scores
N90, according to the CBCL manual).
Cognitive functioning at the time of inclusionwas classiﬁed in a con-
sensus meeting by a child neurologist, neuropsychologist, and clinical
geneticist and rated on a ﬁve-point scale based on available data on in-
telligence quotient (IQ) and developmental level, (1 = no ID (IQ or de-
velopmental quotient (DQ) N85), 2 = borderline ID (IQ or DQ 70–85),
3 = mild ID (IQ or DQ 50–70), 4 = moderate ID (IQ or DQ 30–50),
5 = severe or profound ID (IQ or DQ b30)).When no (recent) IQ or DQ
was available, the assessment was made based on school functioning,
communication, and/or adaptive behavior. All participants were
categorized into two clinical subgroups: Dravet syndrome or non-
Dravet syndrome. Dravet syndromewas diagnosed based on previously
published criteria [36]. The diagnoses were in line with recently
published recommendations [37]. The non-Dravet group consisted of
patients with either GEFS+ or FS. Seizure severity was classiﬁed
based on seizure frequency for both minor seizures (deﬁned as short
absences, short focal seizures, or myoclonias) and major seizures
(deﬁned as all other seizure typeswith loss of consciousness or prolonged
seizures) at the time of inclusion (score 4 = daily seizures, score 3 =
weekly seizures, score 2 = monthly seizures, score 1 = yearly
seizures, score 0 = seizure-free (N1 year)).
2.3. Descriptive analyses
Data on major disease outcomes (cognitive functioning, seizure
severity, walking difﬁculties, behavioral problems, and HRQoL) are
reported as total counts, percentages, or mean/median scores for all
patients, and additional detailed clinical information (on seizure
frequency, antiepileptic drug (AED) use, learning problems, and psy-
chological/behavioral problems) is reported per age group for patients
with non-Dravet syndromes.
2.4. Statistical analyses
No statistical testingwas performed to formally assess differences in
outcomes between patients with Dravet and non-Dravet syndromes,
since these outcomes were used to classify each patient and therefore,
differ per deﬁnition between the groups. Correlations between different
outcomes were calculated with Spearman's rank-order correlation.
Differences between groups were calculated with either Pearson's
chi-square test or Fisher's exact test for binary and categorical variables
or a Mann–Whitney U test for continuous and ordinal variables.
Statistical analyses were performed using SPSS statistics software
(IBM SPSS Statistics for Windows V21, Armonk, NY: IBM Corp.).
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niﬁcance of p b 0.05. Correlations for the non-Dravet group only were
only investigated for the group of patients below 20 years old, because
childhood learning and behavioral problems may not have been
reported reliably for older patients because of recall biases.
3. Results
The characteristics of the study population are depicted in Table 1.
The Dravet syndrome subgroup consisted of 116 patients belonging
to 112 different families, and the non-Dravet group consisted of
48 patients belonging to 28 different families. Six families had
members in both the Dravet and non-Dravet categories. The median
age of patients with Dravet syndrome and patients with non-DravetTable 1
Characteristics of the study population.
n
Age median (years, range)














– 1: no ID (IQ or DQ N85)
– 2: borderline ID (IQ or DQ 70–85)
– 3: mild ID (IQ or DQ 50–69)
– 4: moderate ID (IQ or DQ 30–49)
– 5: severe or profound ID (IQ or DQ b30)
Slowing of development after ﬁrst year of life (yes, n)
Development of epilepsy with multiple seizure types (yes, n)













– Completed questionnaires (n)
– Average total score (range)
Behavioral problemsd
– Completed ABCL/CBCL questionnaires (n)
– Clinical range (n)
– Behavioral problems reported by parents during telephone interview
FMS scoree (n)
– Uses a wheelchair (1)
– Independent walking on ﬂat surfaces (5)
– Independent walking on all surfaces (6)
– Missing
a Based on available data on IQ and developmental level, adjusted for age at assessment
functioning, communication, and adaptive behavior.
b Currently. 4=daily seizures, 3=weekly seizures, 2=monthly seizures, 1=yearly seizure
Major seizures: all other seizure typeswith loss of consciousness or prolonged seizures. Number
c Quality-of-life total score, based on results of PedsQL Measurement Model questionnaire. S
d Clinical range: patients that score N90% on the “total problems” scale on the Child Behavio
e Scoresmeasured by the FunctionalMobility Scale (FMS) to classify functionalmobility for c
3, or 4 (uses a walker or frame, uses crutches, or uses sticks, respectively).syndromes was 14 years and 22 years respectively. Important differ-
ences between both groups were seen for all ﬁve major outcomes.
3.1. Cognitive outcome
All patients could be assessed for cognitive outcome. Almost half of
all patients with Dravet syndrome had a severe cognitive disability
(score 5, 45%) whereas almost all patients with non-Dravet syndromes
had normal cognitive capacities (score 1, 90%) except for ﬁve, whohad a
slight delay (score 2, 10%) (Table 1). Since cognitive functioning is a
deﬁning characteristic used to classify Dravet syndrome, this is an
expected outcome. Cognitive disabilities worsened with age in patients
with Dravet syndrome; over 60% of patients of 20 years and older had a
score of 5, in contrast to only 25% of patients aged 7–8 years (Fig. S1).Complete cohort Dravet Non-Dravet
164 116 48






83 (51%) 65 (56%) 18 (38%)
87 (53%) 44 (38%) 43 (90%)
58 29 29
29 15 14
16 (10%) 13 (11%) 3 (6%)
61 (37%) 59 (51%) 2 (4%)
46 3 (3%) 43 (90%)
15 10 (9%) 5 (10%)
20 20 (17%) 0 (0%)
31 31 (27%) 0 (0%)
52 52 (45%) 0 (0%)
106 (65%) 97 (87%)
(4 missing)
9 (19%)
133 (83%) 113 (97%) 20 (44%)
43 (26%) 8 (7%) 35 (73%)
27 (17%) 16 (14%) 11 (23%)
27 (17%) 25 (22%) 2 (4%)
51 (31%) 51 (44%) 0
16 (10%) 16 (14%) 0
76 (46%) 31 (27%) 45 (94%)
9 (6%) 7 (6%) 2 (4%)
8 (5%) 8 (7%) 0
23 (14%) 23 (20%) 0
48 (29%) 47 (41%) 1 (2%)
93 71 22
61.1 (13–99) 52.6 (13–86) 88.5 (63–99)
122 80 42







26 (31%) 26 (41%) 0
19 (23%) 19 (30%) 0
38 (46%) 18 (29%) 20 (100%)
81 53 28
. When no (recent) IQ or DQ was available, the assessment was made based on school
s, and 0=seizure-free.Minor seizures: short absences, short focal seizures, ormyoclonias.
s of participants are given for dichotomized scores (score 0–1= rarely, score 2–4=often).
caled 0–100; a higher score indicates a higher health-related quality of life.
r Checklist 1.5–5, 6–18 years, or the Adult Behavior Checklist 18–59 years.
hildren aged 4–18 years. Scores for the 500-meter range are used. No participants scored 2,
255I.M. de Lange et al. / Epilepsy & Behavior 90 (2019) 252–259Interestingly, nine patients with non-Dravet syndromes experienced a
slowing of development after the ﬁrst year of life as well; however, in
two cases, the delay was only temporary, and none of these patients
developed ID.
3.2. Seizure severity
All patients could be assessed for seizure frequency. Many patients
with Dravet syndrome experienced major seizures weekly (44%) and
minor seizures daily (41%). In the non-Dravet group, both major and
minor seizures occurred much less frequently, with most patients
being seizure-free at the time of inclusion (73%) (Table 2). If seizures
did still occur in the non-Dravet group, theseweremostly yearly events
(23%). The youngest patients with non-Dravet syndromes had most
seizures: only 38% of 4- to 9-year olds were seizure-free whereas 82%
of 10- to 19-year olds and 100% of patients older than 40 years were
seizure-free. Although 71% of patients with non-Dravet syndromes
had used maintenance treatment, 60% was medication-free at the
time of inclusion. Larger percentages of older patients were medica-
tion-free than younger patients were medication-free than younger
patients (87% of 40+-year olds versus 38% of 4- to 9-year olds).
Interestingly, one patient with non-Dravet syndrome experienced
minor seizures (myoclonias) daily. This 16-year old girl used to have
generalized tonic–clonic seizures but had been seizure- and medica-
tion-free between ages 4 and 10 years old, after which seizures
reappeared. At the time of study, she had monthly focal seizures with
impaired awareness and a few myoclonias per day while being treated
with topiramate and levetiracetam. She was not diagnosed with Dravet
syndrome because she had a normal intellect (IQ 91), and her seizure
course is unusual for Dravet syndrome.
3.3. Functional mobility
Sixty-three patients with Dravet syndrome and 20 patients with
non-Dravet syndromes could be assessed for functional mobility.
Patients with Dravet syndrome showed either no walking disabilities
(independent walking on all surfaces, score 6), minor walking disabil-
ities (independent walking on level surfaces, score 5), or used a wheel-
chair (score 1) on a 500-meter range. Over 40% of patients with DravetTable 2









n 48 13 (27%)
Major seizure frequencya (n)
– Seizure-free 35 (73%) 5 (38%)
– Yearly seizures 11 (23%) 8 (62%)
– Monthly seizures 2 (4%) 0
– Weekly seizures 0 0
– Daily seizures 0 0
Minor seizure frequencya (n)
– Seizure-free 45 (94%) 12 (92%)
– Yearly seizures 2 (4%) 1 (8%)
– Monthly seizures 0 0
– Weekly seizures 0 0
– Daily seizures 1 (2%) 0
AEDb use (n)
– Has at some point used maintenance treatment 34 (71%) 11 (85%)
– Currently no maintenance treatment 29 (60%) 5 (38%)
Learning problemsc (n) 13 (27%) 4 (31%)
Psychological/behavioral problemsd (n) 18 (38%) 5 (38%)
a Currently. Minor seizures: short absences, short focal seizures, or myoclonias. Major seizur
b Antiepileptic drugs.
c Any problem for which extra educational assistance is necessary: e.g., special education, re
d Answered “yes” to the question “are there any behavioral issues?” or behavioral issues
medical ﬁles.syndrome already used a wheelchair at age 4–8 years; this was 50% at
14–18 years (Fig. 1). Patients with non-Dravet syndromes did not
show any walking disabilities on the FMS.
3.4. Behavioral problems
Eighty patients with Dravet syndrome and 42 patients with non-
Dravet syndromes could be assessed for behavioral problems by
CBCL/ABCL questionnaires. Thirty-seven patients (30%) showed behav-
ioral problems in the clinical range (Table 1); all but three were patients
with Dravet syndrome (43% versus 7%). One of the patients with non-
Dravet syndromes with behavioral problems in the clinical range is a
32-year-old father of a son with Dravet-syndrome, who was found to be
mosaic for their pathogenic SCN1A variant in previous research [30,38].
Since his epilepsy was well controlled and no ID was present, he was
not diagnosed with Dravet syndrome; he, however, does have psycho-
social problems, among which an autism spectrum disorder, an active
substance addiction, and aggressivity. The second patient (14 years
old) has an autism spectrum disorder and an IQ of 90; she has been
seizure-free since 2.5 years but has previously experienced different
seizure types, including multiple absences per day. The third patient is
28 years old and has a normal intellect but was schooled at a low level
and now works in a sheltered environment because of his epilepsy
and memory problems. He has around 10 generalised tonic-clonic
seizures (GTCS) per year. Most behavioral problems in the clinical
range were reported in younger patients with Dravet syndrome: 60%
of 4- to 11-year olds score within the clinical range whereas less than
30% of 20+-year-old patients do (Fig. 2A). One hundred six patients
with Dravet syndrome and 27 patients with non-Dravet syndromes
could be assessed for behavioral problems during the telephone inter-
view. Parents of patients responded “yes” to the question “are there
any behavioral problems?” during the telephone interview in 66% of
the patients with Dravet syndrome while only 7% did in patients with
non-Dravet syndromes (Table 1). The CBCL/ABCL data were missing
for 36 patients; similar percentages of parents reported behavioral
problems during the telephone interview for patients with andwithout
CBCL/ABCL results. Most behavioral problems were reported during the
telephone interview for patients with Dravet syndrome between 8 and
















11 (23%) 9 (19%) 15 (31%)
9 (82%) 6 (67%) 15 (100%)
1 (9%) 2 (22%) 0
1 (9%) 1 (1%) 0
0 0 0
0 0 0
10 (91%) 8 (89%) 15 (100%)
0 1 (11%) 0
0 0 0
0 0 0
1 (9%) 0 0
9 (82%) 6 (67%) 8 (53%)
7 (64%) 4 (44%) 13 (87%)
6 (55%) 3 (33%) 0
5 (45%) 5 (56%) 3 (20%)
es: all other seizure types with loss of consciousness or prolonged seizures.
peating a class, extra support needed.












Fig. 1. Functional Mobility Scale (FMS) scores on a 500 m range per age group. Scores range from 1 to 6, although patients only scored 1 (“uses wheelchair”), 5 (“independent on level
surfaces”), or 6 (“independent on all surfaces”).
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Seventy-one patients with Dravet syndrome and 22 patients
with non-Dravet syndromes could be assessed for HRQoL. Patients
with Dravet syndrome showed lower HRQoL scores than patients with
non-Dravet syndromes (average 52.6 versus 88.5, Table 1, Fig. 3). Scores
tended to worsen with age (Fig. S2).3.6. Learning and behavioral problems among patients with non-Dravet
syndrome
Although patients with non-Dravet syndromes were signiﬁcantly
less affected on all ﬁve major outcome scales than patients with Dravet
syndrome, we did observe subtle problems in this group (Table 2).
Twenty-seven percent had encountered some kind of learning
problem for which extra educational assistance was necessary (see
Supplementary data 1 for speciﬁc problems). None of the patients
over 40 years old reported to have experienced problems while
following primary or secondary education.
Behavioral problems, like attention-deﬁcit, autistic features, or anx-
iety, were reported for 38% of patients with non-Dravet syndromes
among all age groups, although their CBCL score was not in the clinicalA         ABCL/CBCL questionnaires                 
Fig. 2. A: Percentage of patients with behavioral problems in the clinical range according to
responded “yes” to the question “are there any behavioral problems?” during the telephone inrange except for three. Two of these 18 patients had not completed the
CBCL questionnaires (see Supplementary data 1 for speciﬁc problems).
3.7. Correlations between outcomes
In the complete cohort, FMS scores were strongly related to
cognitive outcomes, seizure severity, and QoL scores: patients with
more severe walking disabilities had a more severe cognitive dis-
ability (rs = −0.682, p b 0.0005, Fig. S3A), a higher seizure fre-
quency (rs = −0.537 for major seizures and rs = −0.492 for
minor seizures, both p b 0.0005, Fig. S3B), and a lower QoL score
(rs = 0.668, p b 0.0005, Fig. S3C). Most behavioral problems were
observed in patients with a mild cognitive disability (Fig. 4A, B); less
behavioral problems were seen in patients with cognitive outcome
scores on both ends of the spectrum. Behavioral problems in the clinical
range of the ABCL/CBCL questionnaires were positively related to major
seizure frequency (rs = 0.260, p = 0.004, Fig. S4A) in the complete
cohort; however, in patients with Dravet syndrome, most behavioral
problems were reported in patients that are seizure-free or experience
daily seizures (Fig. S4B). Furthermore, patients with behavioral prob-
lems in the clinical range scored signiﬁcantly lower on the QoL ques-
tionnaire (rs =−0.523, p b 0.0005, Fig. S4C). In the complete cohort,
cognitive outcome scores were signiﬁcantly related to major seizuresB        Parent report telephone interview
CBCL/ABCL questionnaires, per age group. B: Percentage of patients for which parents
terview, per age group.
Fig. 3. Distribution of PedsQL scores to indicate health-related quality of life (HRQoL) for
patients with Dravet syndrome and non-Dravet syndromes.
257I.M. de Lange et al. / Epilepsy & Behavior 90 (2019) 252–259(rs = 0.693, p b 0.0005) and minor seizure frequencies (rs = 0.511,
p b 0.0005) (Fig. S5A, B).
In the non-Dravet group only, the presence of any learning
problems was signiﬁcantly associated with a lower QoL score
(median score of 86.45 versus 92.95, p = 0.006 (Mann–Whitney U,
U = 19, z = −2.708), Fig. S6A). No statistically signiﬁcant differ-
ences in QoL scores were found between patients with and without
psychological/behavioral problems (p = 0.188, Fig. S6B). Patients
with psychological or behavioral problems more often used AEDs
than patients without these problems (p=0.013, χ2-test). No differ-
ences in percentages of medication-free patients were observed
between patients with and without learning problems (p = 0.408,
χ2-test). Furthermore, no differences in percentages of seizure-free
patients were observed between patients with and without learning
problems (p = 0.421, χ2-test) or psychological or behavioral
problems (0.421, Fisher's exact test).
4. Discussion
No universally used consensus guidelines for the diagnosis of Dravet
syndrome exist, and many studies use different criteria [37,39–41].
The main diagnostic criteria in most studies relate to the epilepsy phe-
notype and cognitive development. Walking disabilities and behavioralA
n=50 n=15 n=20 n=31 n=52
Fig. 4. A: Percentage of patients with behavioral problems in the clinical range according to AB
parents responded “yes” to the question “are there any behavioral problems?” during the telepproblems are usually not included, even though many studies have
already acknowledged that they are common and important features
of Dravet syndrome [6–9,18,19,37,42] while they are virtually never
present in patients with non-Dravet syndromes with pathogenic SCN1A
variants. Both walking disabilities and behavioral problems can emerge
early in the disease course of Dravet syndrome, affecting a large
percentage of patients before the age of 8 years; 79% of children with
Dravet syndrome between 4 and 8 years in our cohort had a walking
disability, which is in line with recent research [19]. Gait disturbances
have already been described in patients as young as 2 years of age
[9,19]. Our overall percentage of patients with Dravet syndrome with a
walking disability (score 5 or lower, 54%) is between percentages
previously reported: Brunklaus et al. [7] found a motor disorder in 36%
of patients with Dravet syndrome whereas Lagae et al. [19] found
walking disabilities in 79%. These differences are likely due to used
deﬁnitions; factors such as skeletal malalignment, behavioral issues,
epilepsy severity, and pain can affect functional mobility as well.
Furthermore, the FMS assesses functional mobility on a distance of
maximal 500 m while other studies incorporated no distances [19].
Behavioral problems in the clinical range were most frequently seen
between 4 and 11 years of age, when assessed by CBCL/ABCL question-
naires. This is in contrast to previous studies that have found an increase
of behavioral problems with age (although these problems had been
observed in children b2 years of age already) [7,19]. Our different
results might be due to differences in measurement tools and data
collection. Interestingly, parents of patients with Dravet syndrome re-
ported behavioral problems more frequently in the interview (66%)
than patients scored in the clinical range of the CBCL/ABCL question-
naires (43%); this might indicate that scores in the subclinical range are
perceived to be very burdensome as well. This high percentage
underlines the impact of these issues on families and the importance
of accurate management. Behavioral problems were much more
common among patients with Dravet syndrome than in patients
with non-Dravet syndromes (43 versus 7%), and the three patients
with non-Dravet syndromes that scored in the clinical range of the
ABCL/CBCL questionnaires had a relatively severe non-Dravet SCN1A
phenotype. Our data suggest that walking difﬁculties and behavioral
problems, based on ofﬁcial assessments, could be useful when counsel-
ing patients with SCN1A pathogenic variants; they are strong indicators
for a more severe disorder when observed at a young age.
Both walking disabilities and behavioral problems showed a strong
correlation with cognitive outcomes, seizure frequencies, and QoL
scores. Similar ﬁndings have been reported previously, and behavioral
problems have been identiﬁed as the most important predictors of a
worse HRQoL score [7,19]. Interestingly, the relationship between
cognitive disability and frequency of behavioral problemswas not linearB
n=50 n=15 n=20 n=31 n=52
CL/CBCL questionnaires, per cognitive outcome score. B: Percentage of patients for which
hone interview, per cognitive outcome score.
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reason for this could be that more severely disabled patients are less
capable of aberrant behavior; however, it might also be due to the fact
that CBCL questionnaires have been proven to be less reliable in the
assessment of children with moderate, severe, or profound ID [43]. Total
scores cannot be calculated when many questions are not applicable
because of cognitive impairment, which occurs more frequently in
patients with a worse cognitive outcome. Nevertheless, when parents
were asked if they thought their child showed any behavioral problems,
a similar pattern was observed. A hyperbolic relationship was also
found between seizure frequency and behavioral problems in Dravet
syndrome, although inversed: most behavioral problems were seen in
patients that were seizure-free or experienced daily seizures. This nonlin-
ear relationship indicates that behavioral problems are not completely
subject to an epileptic encephalopathy disease model, as previously
suggested [19,44]. Recent research has shown that SCN1A variants could
lead to changes in the dopamine system that may contribute to behav-
ioral problems, irrespective of seizure activity [45]. This, together with
the large impact of behavioral problems on HRQoL scores and the high
number of families affected by it, calls for more attention regarding
recognition of behavioral problems. Handling these issues and developing
coping strategies for parents require more emphasis during treatment,
which should not only focus on suppressing seizures.
Patients with non-Dravet syndromes seem to have a good prognosis:
the majority of our patients was reported to be seizure-free after
10 years of age, and seizure freedom was reported for all patients
over 40 years of age, in most cases, without maintenance treatment.
However, some of the older participants represented parents of children
with SCN1A-related seizures that were tested subsequently after a
diagnosis was made in their children. They may have gone undiagnosed
if their children had not been assessed for mutations, and our results
may therefore not be fully applicable to young probands with SCN1A-
related epilepsy. Seven of the 15 patients in the 40+ age group were
parents of affected children and had never used antiepileptic medica-
tion themselves, so it is unlikely that they would have been diagnosed
individually. It is, furthermore, worth noting that pathogenic SCN1A
variants do not have a 100% penetrance: although our study only de-
scribes symptomatic patients, we are aware of four mutation-carrying
GEFS+ family members that never experienced any seizures (not
included in this study). However, although patients with non-Dravet
syndromes showed better outcomes on the used questionnaires, subtle
comorbidities were still observed in this group. It is known that
neuropsychological and cognitive problems are common in epilepsy
in general [46–50], and it is, therefore, not surprising that similar prob-
lems are observed in the non-Dravet group. Although the use of differ-
ent methods makes comparing the exact results difﬁcult, and we
investigated a small cohort (only 24 patients with non-Dravet syn-
dromes b20 years of age), we, nonetheless, observe relatively similar
percentages of problems in our patient group and cohorts consisting
of patients only diagnosed with epilepsy: 26% of patients between 7
and 16 years old in our cohort had repeated a grade, and 60% required
special educational assistance compared with 26% and 51% respectively
in an epilepsy cohort [48]. Psychological/behavioral problems were
observed in 40% of patients between 5 and 17 years old and in 37% of
patients over 16 years old in our cohort, compared with 31.4% in
children with childhood seizures [49] and versus 30.6% in patients
with epilepsy [47] in the same age groups. Furthermore, similar per-
centages of patients with symptoms of attention deﬁcit hyperactivity
disorder (ADHD) (10% vs 14.3%), depression (5% vs 4%), and anxiety
(15% vs 12.3%) were seen in patients between 5 and 17 years old in
our cohort and in patients with idiopathic epilepsy respectively [46].
Although according to the International League Against Epilepsy
(ILAE), criteria [51], usually, no developmental impairments are
expected in non-Dravet SCN1A phenotypes, we report ﬁve patients
with non-Dravet syndromes (10%) with a cognitive outcome score
of 2 (borderline ID). Their disorder could not be classiﬁed as Dravetsyndrome, since they were seizure-free withminimal or nomedication
at the time of inclusion, and three had never developed any secondary
seizure types. Furthermore, a borderline ID (IQ 70–85) represents the
IQ score range between−1 and−2 standard deviation (SD) from the
mean (100) and is thus observed in 13.6% of the general population.
It can consequently be expected to also occur in a small part of the
non-Dravet group, as described by several authors [27–29]. In addition,
borderline ID might be a family characteristic in these patients. We
therefore argue that a slight cognitive impairment does not necessarily
indicate a diagnosis of Dravet syndrome.
Our study has several limitations. In the non-Dravet group, all of the
more subtle problems (not captured by the standardized question-
naires) were reported by patients or their parents during telephone in-
terviews or mentioned by clinicians in medical ﬁles, and no ofﬁcial
assessments were used to evaluate the problems. Our results therefore
reﬂect issues that they regardedmost important, rather than structured
measurements and may be subject to recall and response biases. To
minimize this effect, we limited our analyses in this group to patients
younger than 20 years. In these patients, the occurrence of problems
at school was independent of seizure and/or medication freedom at
the moment of inclusion. These problems may however, already have
occurred while medication was still being used or when seizures were
still active, so we cannot exclude a causal relationship. Interestingly,
although psychological/behavioral problems occurred independently
of seizure freedom, they occurred more often in patients that still used
medication. This implies that psychological/behavioral problems
might at least be partly due to medication side effects. In other studies
however, no such relation was found [46,48]. It is worth noting that
although signiﬁcantly lower QoL scores were found in patients with
problems at school, the average QoL scores of the non-Dravet group is
comparable with that of the general population [33].
By analyzingmultiple outcomes in patientswith Dravet syndrome to-
gether with patients showing milder SCN1A-related phenotypes, we are
able to assess different disease burdens over a large part of the SCN1A-
spectrum. Both groups show distributions at different ends of the
spectrum, and in general, a clear distinction between these syndromes
can therefore be made, not only based on regularly used clinical criteria
such as cognitive impairment and seizure severity but also on other co-
morbidities: severe behavioral problems and walking disabilities, which
can already occur at a young age in patients with Dravet syndrome and
are almost never seen in patients with non-Dravet syndromes. These is-
sues should receive speciﬁc attention during clinical management of
the disease. However, as in patients with other epilepsies, comorbidities
occur in a substantial part of patients with non-Dravet syndromes as
well. Although these problems are less severe than in patients with
Dravet syndrome, they can still have a large impact on patients and
their families. Our study provides valuable information on the disease
course and comorbidities in these patients, which can be of great
value when counseling newly diagnosed patients and their parents.
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